Revive Therapeutics: Initiation report
Revive Therapeutics (CSE:RVV, OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases. The company has a pipeline comprising three main platforms:
Bucillamine for treatment of infectious diseases including COVID-19:
Bucillamine (BUC) is a medication with a well-established safety profile having been prescribed for arthritis for more than 30 years. Revive Therapeutics has been working with BUC for five years as a repurposing opportunity and has obtained two Food and Drug Administration (FDA) INDs (investigational new drug applications) with BUC to treat gout flares and cystinuria. During 2020 the company has made an IND filing concerning the use of BUC to treat COVID-19 with intellectual property around infectious diseases.
BUC has shown significant potential to reduce lung inflammation damage associated with a serious infection, and could, therefore, reduce fatalities from COVID-19. The company received a recommendation from the FDA that it skip Phase 2 trials and make an application to move immediately to Phase 3. If this trial proceeds and begins to deliver results, we believe this would be a major catalyst for the share price. We examine this opportunity on p3-5.
Quick facts: Revive Therapeutics
Price: 0.255 CAD
Market Cap: $41.81 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE